Management of moderate to severe Alzheimer's disease: Focus on memantine
Alzheimer's disease (AD) is the most common form of dementia, and one of the principal causes leading to death around the world. It is a progressive neurodegenerative disorder that still remains without definite cure. Memantine, a licensed AD drug, is an open-channel and partial trapping blocke...
Saved in:
Main Authors: | Evangelyn Dominguez (Author), Ting-Yu Chin (Author), Chih-Ping Chen (Author), Tzong-Yuan Wu (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2011-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dual Action of Memantine in Alzheimer Disease: A Hypothesis
by: Tzong-Yuan Wu, et al.
Published: (2009) -
Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer’s disease
by: Chang W, et al.
Published: (2018) -
Virtual Therapy with the NMDA Antagonist Memantine in Hippocampal Models of Moderate to Severe Alzheimer's Disease, in Silico Trials
by: Dariusz Świetlik, et al.
Published: (2022) -
A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
by: Deardorff WJ, et al.
Published: (2016) -
Alzheimer's Disease: Aging, Insomnia and Epigenetics
by: Tzong Yuan Wu, et al.
Published: (2010)